These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 10197639)
1. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Tozer GM; Prise VE; Wilson J; Locke RJ; Vojnovic B; Stratford MR; Dennis MF; Chaplin DJ Cancer Res; 1999 Apr; 59(7):1626-34. PubMed ID: 10197639 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635 [TBL] [Abstract][Full Text] [Related]
3. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Prise VE; Honess DJ; Stratford MR; Wilson J; Tozer GM Int J Oncol; 2002 Oct; 21(4):717-26. PubMed ID: 12239609 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Tozer GM; Prise VE; Chaplin DJ Cancer Res; 1997 Mar; 57(5):948-55. PubMed ID: 9041200 [TBL] [Abstract][Full Text] [Related]
5. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406 [TBL] [Abstract][Full Text] [Related]
6. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Parkins CS; Holder AL; Hill SA; Chaplin DJ; Tozer GM Br J Cancer; 2000 Sep; 83(6):811-6. PubMed ID: 10952787 [TBL] [Abstract][Full Text] [Related]
7. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Chaplin DJ; Pettit GR; Hill SA Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542 [TBL] [Abstract][Full Text] [Related]
11. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015 [TBL] [Abstract][Full Text] [Related]
13. Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumor. Bell KM; Prise VE; Chaplin DJ; Tozer GM J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S222-5. PubMed ID: 8587370 [TBL] [Abstract][Full Text] [Related]
14. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Pedley RB; Hill SA; Boxer GM; Flynn AA; Boden R; Watson R; Dearling J; Chaplin DJ; Begent RH Cancer Res; 2001 Jun; 61(12):4716-22. PubMed ID: 11406542 [TBL] [Abstract][Full Text] [Related]
15. Hemorrhagic shock-induced vascular hyporeactivity in the rat: relationship to gene expression of nitric oxide synthase, endothelin-1, and select cytokines in corresponding organs. Liu LM; Dubick MA J Surg Res; 2005 May; 125(2):128-36. PubMed ID: 15854664 [TBL] [Abstract][Full Text] [Related]
16. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357 [TBL] [Abstract][Full Text] [Related]
17. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses. Tozer GM; Prise VE; Lewis G; Xie S; Wilson I; Hill SA Clin Cancer Res; 2009 Jun; 15(11):3781-90. PubMed ID: 19470729 [TBL] [Abstract][Full Text] [Related]
18. Effects of nitric oxide synthase inhibition on blood flow and survival in experimental skin flaps. Gribbe O; Samuelson UE; Wiklund NP J Plast Reconstr Aesthet Surg; 2007; 60(3):287-93. PubMed ID: 17293287 [TBL] [Abstract][Full Text] [Related]
19. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969 [TBL] [Abstract][Full Text] [Related]
20. Effects of nitric oxide donor and nitric oxide synthase inhibitor on the resistance, exchange and capacitance functions of the canine intestinal vasculature. Hsieh NK; Chang HR; Hu CT; Chen HI Vascul Pharmacol; 2008; 48(2-3):122-8. PubMed ID: 18295548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]